$QTRX

Quanterix Corporation appointed Geoff Albrecht as senior vice president and general manager of Diagnostics. Albrecht, with over 25 years of experience at Quest Diagnostics, will lead the development of Quanterix's Diagnostics strategy, focusing on Alzheimer’s Disease Diagnostics. Quanterix aims to scale its Diagnostics portfolio into a significant revenue driver, reporting to CEO Everett Cunningham.

Quanterix (QTRX) said Q2 2026 revenue was about $3 million (9%) below May guidance, citing broad-based shortfalls and commercial execution challenges. The company lowered 2026 revenue guidance to $142 million to $148 million from $169 million to $174 million and expects ~$80 million cash by year-end. Quanterix added commercial leaders (Jim Gute, Geoff Albrecht) and reorganized sales, citing Akoya integration savings of $85 million annually.

Quanterix (QTRX) said it completed Akoya Biosciences integration in Q2 and delivered $85M in revenue synergies. It is reshaping sales teams and expects clinical-trial bookings to rise QoQ. For its LucentAD Complete Alzheimer’s blood test, Quanterix filed a 510(k) in January and targets an FDA decision in Q4, possibly into Q1, citing a CMS price crosswalk of $897. It targets $10M diagnostics revenue in 2026.

DONNELLY WILLIAM P purchased 99,400 indirectly-held shares of Quanterix Corp (QTRX) at an average of $2.88 ($2.75–$2.93, $0.29M total) across 2 trades over 2026-08-12 to 2026-08-13.

Quanterix (NASDAQ:QTRX) reported Q2 cash use of $5.7M and cash of $96.9M. Simoa revenue was $20.6M, Spatial $12.3M, and GAAP gross margin 38.5%. Management guided Q3 revenue flat to slightly above Q2 and cited Akoya integration, $85M annualized savings, and commercial reorganization. FDA timing for LucentAD Complete is targeted for late 2026.

Quanterix Corp (QTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quanterix Releases Financial Results for the Second Quarter of 2026 Reports $32.9 million in revenue and $96.9 million of cash and marketable securities Company accelerating initiatives to drive commercial effectiveness Revises financial outlook for 2026 and extends

Meadows Benjamin (Chief Commercial Officer) purchased 3,500 shares of Quanterix Corp (QTRX) at $2.77 on 2026-05-12.

Quanterix Corp (QTRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. qtrx-20260609 Quanterix Corp false 0001503274 0001503274 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ FORM 8-K ______________________________________ CURRENT REPORT Pursuant to Section 13 or 1

Quanterix Corp. (QTRX) appointed Jason Faessler as CFO effective June 22, succeeding Vandana Sriram, who has served since August 2023 and will step down. Faessler joins from Bruker Corp., where he led global FP&A and Americas finance. Shares fell in premarket, down 3.09% to $3.0332 after a 5.15% decline Monday.

Quanterix Corp (QTRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 exhibit101-qtrxx20260609.htm EX-10.1 Document Exhibit 10.1 Quanterix 900 Middlesex Turnpike | Building 1 Billerica, MA 01821 Jason Faessler Delivered via Email Re: Employment Agreement Dear Jason: Quanterix Corporation (the "Company") is pleased to offer you the full-ti